Worldwide Liquid Biopsy (LBx) Market Forecasted to Grow at 29% p.a., Reaching $10.1B by 2029 – Market Report by DeciBio Consulting LLC
25 Julio 2024 - 8:30AM
Business Wire
According to a comprehensive market report authored by DeciBio
Consulting LLC, “Oncology Liquid Biopsy (LBx) Market Report 2024 –
2029,” the global oncology liquid biopsy market is predicted to
reach $10.1B by 2029, driven by a broad push for increased
biomarker testing globally, updated testing guidelines, and
expansion in coverage for testing.
This third-edition of DeciBio’s liquid biopsy report takes an
updated and comprehensive look at the LBx landscape. Informed by a
combination of primary research, secondary research, and
proprietary DeciBio databases and tools, this report provides a
quantitative and qualitative assessment of the key LBx market
segments.
Advancements in sensitivity and analytical capabilities are
expanding the use-cases for liquid biopsy beyond genomic profiling
to include minimal / molecular residual (MRD) testing, recurrence
monitoring (surveillance), treatment response monitoring, and early
cancer detection. While nascent today, these new applications
represent significant global market expansion opportunities.
Report Methodology / Scope:
Report Details
Research Methods
- Secondary research: publication analysis of LBx-related
congress abstracts published from 2023-1H 2024, review of company
websites and publications, identification and characterization of
LBx clinical trials
- Primary research: interviews with 38 oncology stakeholders
across the U.S., EU, APAC, and ROW, including oncologists,
pathologists and pharma; survey of 207 primary care physicians and
specialists to assess current and expected future utilization and
perspectives on blood-based early cancer detection testing
- Proprietary databases / analysis: use of internal databases and
tools (e.g., BioTrack, Dexter expert network), including DeciBio’s
Discovery Portal and DeciBio DxBooks
- Market analysis: 4 independent market models, including a mix
of top-down and bottom-up approaches
2029 Market Size
$10.1 billion
CAGR (2024-2029)
29%
Base Year
2024 (current)
Forecast Period
2024-2029
Market / Forecast Currency
USD
Report Coverage
Market size, segmentation, and forecast;
key market players and trends; assays and technologies; market
drivers and moderators; competitive analysis
Segments Covered
- Customer (clinical, biopharma)
- Tumor type (lung cancer, breast cancer, colorectal cancer,
other)
- Application (early cancer detection, therapy selection, minimal
residual disease, monitoring / surveillance, biopharma
translational research)
- Business model (in-house (kits), send-out (services))
- Competitor, grouped into tiers (Foundation Medicine, Guardant,
Caris, Tempus, NeoGenomics, LabCorp, QuestDx, Burning Rock, Natera,
Exact Sciences, Personalis, Illumina, Thermo Fisher, Freenome,
Academic Medical Centers (with a proprietary LBx offering offered
externally), other)
- Geography (U.S., Europe, APAC, rest of the world)
Learn more about DeciBio’s Oncology Liquid Biopsy (LBx) Market
Report 2024 – 2029, here:
https://www.decibio.com/product/global-oncology-liquid-biopsy-manufacturing-market-report
Selection of Liquid Biopsy Companies Mentioned:
- Adela
- AmoyDx
- Berry Oncology
- Biological Dynamics
- Burning Rock Biotech
- Caris Life Sciences
- DELFI Diagnostics
- Exact Sciences
- Foresight Diagnostics
- Foundation Medicine
- Freenome
- Geneseeq Technology Inc.
- Genetron Holdings
- GRAIL
- Guardant Health
- Illumina
- LabCorp / PGDx
- Tempus
- Thermo Fisher Scientific
- Natera
- NeoGenomics (Inivata)
- Personalis
- Predicine
- Roche
- SeekIn
- Singlera Genomics
- Strata Oncology
Liquid Biopsy Market Analysis:
Market Drivers
The liquid biopsy market is poised for growth, driven by new
evidence, updated guidelines, and expanded coverage that support
broader application beyond primary use cases, such as therapy
selection in lung cancer and MRD / monitoring in colorectal cancer.
As new biomarkers emerge and companion diagnostics are approved,
the demand for biomarker testing is on the rise. This increasing
demand puts pressure on limited tissue samples and accelerates the
adoption of LBx testing, particularly as patients become eligible
for multiple LBx tests throughout their treatment journey. The
availability of next-generation LBx assays, featuring improved
performance and the ability to detect emerging biomarkers, expands
the use cases for LBx testing and advances translational research
in pharma. While the U.S. leads in the clinical use of LBx testing,
new partnerships aimed at increasing global access to LBx testing
will support further market growth globally.
Market Moderators
Test cost and the pace and level of payor coverage remains a
challenge for liquid biopsy testing, especially outside of lung
cancer and in ex-U.S. markets. Novel modalities, such as
multiomics-based LBx tests and MRD / surveillance testing, can be
prohibitively expensive to implement at scale in large trials and
similarly, when considering adoption in routine clinical testing.
Early cancer detection, though an application of LBx testing with
high-growth potential, has recently faced headwinds with
lower-than-expected performance in pivotal studies. Additionally,
the broader macroeconomic environment has forced companies to focus
on near-term profitability and to reduce or delay investment and
R&D for emerging applications and use cases.
About DeciBio:
DeciBio Consulting (www.decibio.com) is the leading strategy
consulting, market intelligence, and SaaS firm dedicated to
accelerating the adoption and impact of technologies enabling
precision medicine.
Headquartered in Los Angeles, California, DeciBio serves a
global base of clients and customers, ranging from startups to
Fortune 500 healthcare corporations. DeciBio offers advisory
services for growth planning, market and opportunity assessment,
product and portfolio strategy, voice-of-customer feedback,
technology assessment, and commercial due diligence.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240725768770/en/
Rebecca Burnham rebecca.burnham@decibio.com 310.451.4510